HSBC Downgrades AstraZeneca (AZN) to Underweight
More News related to AZN
- Bristol-Myers Squibb and AstraZeneca to Hold Investor Teleconference to Discuss EASD Highlights
- Survey Shows Parents' Best Intentions Out of Step with Expert Recommendations in Protecting Kids from Flu
- AstraZeneca Announces Innovative New Partnership With Singapore Institutions to Develop Anti-Cancer Compounds
- Abbott (ABT) and AstraZeneca (AZN) to Co-Promote CRESTOR(R)
- Abbott and AstraZeneca Expand Relationship to Include Co-Promotion of CRESTOR(R)
HSBC downgrades AstraZeneca (NYSE: AZN) from Neutral to Underweight, citing slowing revenue outlook for Nexium.
AstraZeneca PLC, incorporated on June 17, 1992, discovers, develops, manufactures and markets prescription pharmaceuticals, biologics and vaccines for principal areas of healthcare, including cardiovascular, gastrointestinal, neuroscience, oncology, respiratory and inflammation, and infection.
Related Categories
DowngradesStocks Mentioned
-0.04Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
